Navigation Links
Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease

Transdermal hormone replacement therapy (HRT) does not reduce the risk of cardiac events in postmenopausal women with existing coronary artery disease (CAD). In the PHASE trial (Papworth HRT Atherosclerosis Study), researchers randomized 255 postmenopausal women with angiographically proven coronary artery disease to receive either transdermal HRT--17-beta-estradiol with or without cyclic norethisterone--or no hormone replacement therapy. The women were followed for 4 years. Overall, 134 women received hormone replacement therapy. Of these, 58 had had a previous hysterectomy. The other 121 women served as controls.

On intention-to-treat analysis, there was no statistical difference in the incidence of unstable angina requiring hospitalization, MI or premature death from heart disease in women receiving HRT and women not receiving the therapy. Respectively, the average event rates were 15.6 and 12.6 per 100 patient-years. Results from the PHASE study also seem to indicate an increased risk of thromboembolic complications, such as stroke, with HRT. This observation is supported by results from the HERS study, a randomized trial carried out in the US that included 3000 women, and was designed to assess the cardioprotective effect of combined HRT in women with documented CAD.

It may therefore be appropriate that women with proven coronary artery disease should not commence HRT. Nevertheless, women receiving HRT for more than 2 years should continue.
'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with CAD
2. Transdermal Vaccine Effective in Treating Alzheimers Disease in Mice
3. Transdermal HRT not cardioprotective in postmenopausal women with CAD
4. Transdermal HRT not cardioprotective in postmenopausal women with CAD
5. Enlarged waistline may predict atherogenesis for postmenopausal women
6. Research explains why postmenopausal women accumulate abdominal fat.
7. Testosterone Therapy can improve sexual function in postmenopausal women
8. Transdermal HRT not cardioprotective in postmenopausal women with CAD
9. Starvation in pregnant women can cause heart disease to their children
10. Brisk Walking lowers memory loss in women
11. Young womens woes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/26/2017)... Baton Rouge, Louisiana (PRWEB) , ... July 26, 2017 , ... ... their doctors to offer the ability for patients to schedule an appointment online in ... LocalMed directly from the Six Month Smiles provider directory will bring more Six Month ...
(Date:7/26/2017)... ... ... M. Musielak, a partner at the Andrew Cores Family Law Group, a division ... earlier this year. She will serve the membership in this capacity for a term of ... the organization’s by-laws. , Musielak joined the Andrew Cores Family Law Group ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... department joining as Regional Account Manager for the Northeast and Florida regions. In ... liquidation of their obsolete medical assets. , Jennifer joins Centurion with a wealth ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus Hyosung America ... today announced its partnership with financial technology company, Automated Transaction Delivery (ATD), to ... solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated software. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Engineers at ... bio-compatible, because it produces the same kind of electrical energy that the body uses. ... form of moving electrons. This flow of electrons out of the battery is generated ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... 20, 2017  Prime Therapeutics LLC (Prime) released this statement ... following today,s Institute for Clinical and Economic Review,s (ICER) ... effectiveness and value of abuse-deterrent formulations (ADF) of opioids. Prime ... at the meeting. ... benefit to the use of abuse-deterrent formulations (ADF) in opioids ...
(Date:7/17/2017)... 17, 2017  MedX Holdings, Inc., the manufacturer and ... and rehabilitation equipment, today announced the national roll out ... considered the gold standard for the treatment of low ... strengthening equipment. How ... physician or practice who prescribe the MedX Home Back ...
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
Breaking Medicine Technology: